IL6, interleukin 6, 3569

N. diseases: 2367; N. variants: 22
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE The neural network model based on WLA and IL-6 could predict the IT of AS. 31039661 2020
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 AlteredExpression disease BEFREE Siphonaxanthin significantly suppressed AGE-induced mRNA expression of interleukin-6 and cellular adhesion molecules, which are known to be important for the pathogenesis of atherosclerosis. 31432315 2020
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 AlteredExpression disease BEFREE Compared with those in the NC group, the serum levels of interleukin-6 (IL-6), IL-10, IL-13 and tumor necrosis factor-α (TNF-α) in the AS group significantly increased (p<0.05). 31002155 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE The anti-oxidant <i>N</i>-acetylcysteine (NAC) not only suppresses IL-6 production and VSMC pathological responses including migration and proliferation but also prevents atherosclerosis in <i>ApoE</i><sup>-/-</sup> mice. 31817202 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE In CANTOS, the magnitude of benefit of this cytokine-targeted approach to atherosclerosis treatment was associated to the magnitude of reduction of the central signaling cytokine IL-6 and the downstream clinical biomarker high-sensitivity CRP (C-reactive protein). 30702995 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE Interleukin-6 (IL-6), a pleiotropic cytokine, plays a key role in endothelial injury and atherosclerosis. 30317657 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE Whether Tet3 has a relationship with atherosclerosis and IL-6 was unknown. 31252000 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 AlteredExpression disease BEFREE The 1-decile greater levels of IL-6 (adjusted HR [aHR], 1.12; 95% CI, 1.08-1.16; P<0.001), TNF-α (aHR, 1.09; 95% CI, 1.05-1.13; P<0.001), fibrinogen (aHR, 1.07; 95% CI, 1.03-1.11; P<0.001), and serum albumin (aHR, 0.96; 95% CI, 0.93-0.99; P<0.002) were independently associated with the composite ASVD-death outcome. 30545708 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE Interleukin-6 (IL-6) is an inflammatory cytokine with a key role in atherosclerosis. 31642412 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE The pro-inflammatory response to interleukin 6 (IL6) trans-signalling in atherosclerosis is driven by the IL6 and soluble IL6 receptor (sIL6R) binary complex. 30052808 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 AlteredExpression disease BEFREE The levels of blood lipids, atherosclerotic plaques (AP) formation, the lipid content, collagen content, apoptosis of aortic cells, angiogenesis as well as the expression of inflammatory factors, such as tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) were determined through a series of experiments.MIAT was found to be upregulated in AS. 31237148 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 GeneticVariation disease BEFREE Because levels of inflammatory cytokines are markedly elevated in patients with chronic kidney disease (CKD), we hypothesized that genotypic variations in the interleukin-6 (IL-6) gene are a cause of systemic inflammatory states and atherosclerosis in South African CKD patients. 31426909 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE Among cells involved in the early steps of atherosclerosis, monocyte-derived dendritic cells (Mo-DCs) respond to inflammatory stimuli, including platelet-activating factor (PAF), by the induction of various cytokines, such as interleukin 6 (IL-6). 31289638 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 AlteredExpression disease BEFREE Moreover, the use of loss- or gain-of-function genetically modified, atherosclerosis-prone mice has provided strong experimental evidence for a causal role of innate and adaptive immunity in atherosclerosis and has revealed the pathogenic activity of proinflammatory cytokines, including TNF (tumor necrosis factor)-α, IL (interleukin)-1β, IL-6, and IL-18, and the atheroprotective effect of anti-inflammatory cytokines, including IL-10 and TGF-β. 31294625 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 AlteredExpression disease BEFREE Infection with an adenovirus delivering the EMMPRIN-siRNA ameliorated AS, promoted macrophage autophagy in plaques and reduced the serum TNF-α, IL-6, MCP-1 and NF-κB expression levels in the AS mice. 29154780 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 AlteredExpression disease BEFREE This study is that ginsenoside Rb1 exerted an inhibitory effect on early atherosclerosis in ApoE-/- mice via decreasing body weight and food intake daily, upregulating the lipid levels of serum plasma, including those of TC, TG and LDL-C and HDL-C and reducing the atherosclerotic plaque area, suppressing inflammatory cytokines (levels of IL-1β, IL-6 and TNF-α) in the serum of ApoE-/- mice, changing the expression levels of BCL-2, BAX, cleaved caspase-3 and cleaved caspase-9 and weakening apoptosis associated with anti-inflammatory activity. 30413028 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE We aimed to evaluate the associations and prognostic value of interleukin-6 (IL6) for the prediction of atherosclerotic cardiovascular disease (ASCVD) events, heart failure (HF), and other chronic diseases in a large, multi-ethnic, contemporary population. 30312930 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 AlteredExpression disease BEFREE These results suggested that appropriate WBV may delay the progression of AS, which was associated with acutely elevated serum IGF-1 and lower levels of IGF-1 and IL-6 in the aorta for long-term treatment. 29707570 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 AlteredExpression disease BEFREE Inflammation relevant genes, such as F4/80, tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, and monocyte chemoattractant protein (MCP)-1, and lipid metabolism associated gene, such as LDL receptor, class A scavenger receptors (SR-A), scavenger receptor class B type I (SR-BI), CD36, ATP binding cassette subfamily A member 1 (ABCA1), and ATP binding cassette subfamily G member 1 (ABCG1) in the aorta were significantly down-regulated in miR-217 group when compared with atherosclerosis group. 30041636 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE IL-6 may play a pivotal role in EREG upregulation by IH and consequently OSA-related atherosclerosis. 29744301 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE IL-6 is an independent predictor of plaque progression, suggesting that it may be a marker of progressive atherosclerosis in the general population and that its central role in CVD may be related to promotion of plaque growth. 29453087 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE New CV events in subjects with T2D with manifest CVD were associated with higher baseline levels of inflammatory biomarkers (interleukin 6, chemokine ligand 3, pentraxin 3, and hs-CRP) and endothelial mitogens (hepatocyte growth factor and vascular endothelial growth factor A), whereas CV events in subjects with T2D without manifest CVD were associated with more severe baseline atherosclerosis (median carotid plaque area 30.4 mm<sup>2</sup> [16.1-92.2] vs. 19.5 mm<sup>2</sup> [9.5-40.5], <i>P</i> = 0.01). 30061319 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 AlteredExpression disease BEFREE Additionally, it was observed that FCs immunization down-regulated the expression level of atherosclerosis related pro-inflammatory cytokines, including IFN-γ, MCP-1, and IL-6 and enhanced the lesion stability with a significant increase in TGF-β1 level and collagen content. 30687328 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE The increased levels of pro-inflammatory cytokines (IL-6, TNF-α, sVE-cadherin) induced by AS were also decreased by baicalin treatment, indicating that baicalin acted as an anti-inflammation regulator in AS. 29793330 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.400 Biomarker disease BEFREE In a large, multi-ethnic population with NAFLD, IL-6 is independently associated with the prevalence and severity of subclinical atherosclerosis. 29579601 2018